The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | First line pembrolizumab in PD-L1 TPS 90%+ NSCLC
Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, discusses findings from a study which focuses on the efficacy of first-line pembrolizumab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) based on their PD-L1 tumor proportion scores (TPS). Patients with PD-L1 TPS ≥90% were compared to those with TPS between 50-89%. Results from a cohort of 516 patients revealed that those with PD-L1 TPS ≥90% experienced significantly longer median progression-free survival (PFS) and overall survival (OS) compared to the 50-89% group. Furthermore, patients with very high PD-L1 expression were more likely to complete a full course of treatment. Genomic analysis showed differences in mutation frequencies, while immunophenotyping demonstrated increased immune cell activity in the ≥90% group. This research highlights the sustained benefits of pembrolizumab in high PD-L1 expression patients and underscores potential treatment implications. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
